Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
239
Stocks News & Analysis
stocks
Is CSL undervalued after earnings season wobble?
The ASX's biggest healthcare name saw its shares fall after reporting first-half results.
stocks
After earnings is Apple stock a buy, sell or fairly valued?
Our thoughts on Apple's stock amid slowing iPhone sales but high services revenue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.60 | 48.00 | 0.55% |
| CAC 40 | 8,028.90 | 22.68 | 0.28% |
| DAX 40 | 22,037.83 | 126.09 | 0.58% |
| Dow JONES (US) | 44,593.65 | 123.24 | 0.28% |
| FTSE 100 | 8,777.39 | 9.59 | 0.11% |
| HKSE | 21,812.89 | 518.03 | 2.43% |
| NASDAQ | 19,643.86 | 70.41 | -0.36% |
| Nikkei 225 | 38,963.70 | 162.53 | 0.42% |
| NZX 50 Index | 12,913.95 | 3.50 | -0.03% |
| S&P 500 | 6,068.50 | 2.06 | 0.03% |
| S&P/ASX 200 | 8,535.30 | 51.30 | 0.60% |
| SSE Composite Index | 3,346.39 | 28.33 | 0.85% |